{"id":163828,"date":"2022-10-11T02:07:47","date_gmt":"2022-10-11T06:07:47","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/nmd-pharma-reports-positive-top-line-data-from-a-phase-i-iia-clinical-trial-of-nmd670-in-patients-with-myasthenia-gravis\/"},"modified":"2024-08-18T11:45:44","modified_gmt":"2024-08-18T15:45:44","slug":"nmd-pharma-reports-positive-top-line-data-from-a-phase-i-iia-clinical-trial-of-nmd670-in-patients-with-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/nmd-pharma-reports-positive-top-line-data-from-a-phase-i-iia-clinical-trial-of-nmd670-in-patients-with-myasthenia-gravis.php","title":{"rendered":"NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis"},"content":{"rendered":"<p><![CDATA[NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis]]><\/p>\n<p>Read the original here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/10\/11\/2531410\/0\/en\/NMD-Pharma-Reports-Positive-Top-Line-Data-from-a-Phase-I-IIa-Clinical-Trial-of-NMD670-in-Patients-with-Myasthenia-Gravis.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis\">NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original here: NMD Pharma Reports Positive Top-Line Data from a Phase I\/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/nmd-pharma-reports-positive-top-line-data-from-a-phase-i-iia-clinical-trial-of-nmd670-in-patients-with-myasthenia-gravis.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-163828","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/163828"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=163828"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/163828\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=163828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=163828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=163828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}